EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Minimal-length CAG repeats in AR define a hyperactive AR–LSD1 axis driving metabolic reprogramming in prostate cancer

Songqi Zhang iD, Muqing Li, Mingyu Liu, Nolan D Patten iD, Maryam Labaf, Jaeweon Jeong, HyeonYeong Sun, Jared Lourie iD, Kai Zou iD, Susan Patalano, Michaela J Mulhearn, Jill A Macoska iD und 6 weitere

Proceedings of the National Academy of Sciences · 2026

DOI: 10.1073/pnas.2534152123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Songqi Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA 02125. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms, Trinucleotide Repeats, Histone Demethylases. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Cancer Institute (NCI), NCI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The polymorphic CAG trinucleotide repeat in the androgen receptor ( AR ) gene encodes a variable-length N-terminal polyglutamine (polyQ) tract that modulates AR transcriptional activity, with shorter tracts generally enhancing AR activity. While the majority of men harbor CAG repeats longer than 17, a small subset carry minimal-length CAG repeats (≤17) in AR . These alleles are primarily found in men of African ancestry, accounting for over 10% of the population, and may significantly contribute to the increased prostate cancer (PCa) risk and worse clinical outcomes observed in this population. However, how this distinct pattern of polymorphism influences AR–chromatin interaction, metabolic reprogramming, and therapeutic response remains unclear. Here, we established isogenic PCa cell lines harboring AR with a minimal length of CAG repeats that encode an ultrashort polyQ tract and found that this AR variant exhibits attenuated response to AR-targeted therapies with markedly enhanced protein stability, expanded chromatin binding, and a reprogrammed transcriptional profile. The ultrashort polyQ AR also reshapes global FOXA1 occupancy and upregulates metabolic gene networks, leading to enhanced glycolysis and reduced mitochondria respiration. Mechanistically, we identify a strengthened AR–LSD1 interaction and show that LSD1 inhibition suppresses the expanded AR chromatin binding, impairs the glycolytic reprogramming, and reduces tumor growth. Together, these findings define a hyperactive AR–LSD1 chromatin axis driven by minimal-length CAG repeats in AR and reveal a mechanistic link between inherited AR polymorphism, AR-mediated epigenetic-metabolic remodeling, and population-associated disparities in prostate cancer biology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, AndrogenProstatic NeoplasmsTrinucleotide RepeatsHistone DemethylasesMaleHumansMetabolic ReprogrammingCell Line, TumorPeptidesGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

LSD1androgen receptorcancer racial disparitypolyglutamine repeatsprostate cancer

Substanzen

Receptors, AndrogenHistone DemethylasesKDM1A protein, humanAR protein, humanpolyglutaminePeptides

Autor:innen und Institutionen

  • Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA 02125.
  • Department of Biology, University of Massachusetts Boston, Boston, MA 02125.
  • Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
  • Department of Mathematics, University of Massachusetts Boston, Boston, MA 02125.
  • Hematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215.
  • Department of Exercise and Health Sciences, University of Massachusetts Boston, Boston, MA 02125.

ORCID-Profile: Songqi Zhang, Nolan D Patten, Jared Lourie, Kai Zou, Jill A Macoska, Shuai Gao, Roberta Andreotti, Dong Han, Steven P Balk, Changmeng Cai

Förderung

  • HHS | NIH | National Cancer Institute (NCI)
  • NCI NIH HHS
  • NIDDK NIH HHS
  • U.S. Department of War (DOW)

Zitieren

APA

Zhang, S., Li, M., Liu, M., Patten, N. D., Labaf, M., Jeong, J., Sun, H., Lourie, J., Zou, K., Patalano, S., Mulhearn, M. J., Macoska, J. A., Gao, S., Andreotti, R., Pennuto, M., Han, D., Balk, S. P., & Cai, C. (2026). Minimal-length CAG repeats in AR define a hyperactive AR–LSD1 axis driving metabolic reprogramming in prostate cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2534152123

Vancouver

Zhang S, Li M, Liu M, Patten ND, Labaf M, Jeong J, et al. Minimal-length CAG repeats in AR define a hyperactive AR–LSD1 axis driving metabolic reprogramming in prostate cancer. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2534152123

BibTeX
@article{Zhang2026,
  author = {Zhang, Songqi and Li, Muqing and Liu, Mingyu and Patten, Nolan D and Labaf, Maryam and Jeong, Jaeweon and Sun, HyeonYeong and Lourie, Jared and Zou, Kai and Patalano, Susan and Mulhearn, Michaela J and Macoska, Jill A and Gao, Shuai and Andreotti, Roberta and Pennuto, Maria and Han, Dong and Balk, Steven P and Cai, Changmeng},
  title = {Minimal-length CAG repeats in AR define a hyperactive AR–LSD1 axis driving metabolic reprogramming in prostate cancer},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  doi = {10.1073/pnas.2534152123}
}
Kostenlos starten →